Complement C3 is a known driver of systemic GVHD (Kwan et al., 2012; Ma et al., 2014; Seignez et al., 2017), and our data show that aberrant complement pathway activation also contributes to the pathogenesis of ocular GVHD including corneal sensation loss. The gene discussed is C3; the disease is graft versus host disease.